Any current/future new fundraising through debt or equity?

The company plans to fund its growth primarily through internal accruals, avoiding the need for additional borrowing. Debt-to-EBITDA ratio is currently at a comfortable level (about 2.3%) and is expected to slightly improve in coming quarters. There will be some capex for maintenance and growth in future years, but this will not require extra borrowing. No specific mention of new equity fundraising in the provided transcript. Investments such as new high-end equipment and clinical talent are being funded through existing resources without raising new debt or equity.

Any current/future capex/capital investment/strategic investment?

Capex for the 9 months this fiscal was about INR 96 crores, including INR 56 crores invested in various areas. Investments made in revenue-generating activities such as: - Solar installation at Karnataka center (~INR 18 crores) reducing electricity cost. - High-end equipment at the center of excellence. - Robotic surgery infrastructure including da Vinci robotic units under pay-per-use model. Future capex includes: - Capacity additions with expected operationalization of installed beds over the next 18 months. - Maintenance and growth-oriented capex will continue. - New centers lik

Future growth expectations in sales/revenue/volumes?

Emerging centers are expected to grow faster than mature centers, driven by increased utilization and new patient volumes (Q&A, Page 16). Continued investment in clinical talent and business promotion will boost future revenues; these investments are temporary and aimed at scalable growth (Page 17). Focus on increasing volumes first in emerging centers before optimizing mix and ARPOB to improve revenue quality (Page 8). Growth drivers for FY '24 remain consistent, including improving utilization of emerging hospitals and expansion of clinical services (Page 15-16). Expansion of capacity with 2

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects continuation of revenue growth momentum in FY '24 driven by emerging and mature centers. Emerging centers are investing in clinical talent and sales to drive scale and utilization, leading to future margin improvement. EBITDA margin currently includes upfront investments but is expected to improve as centers mature, targeting mid-20% unit-level EBITDA margins. Mature centers typically achieve mid-20% EBITDA margin; the company aims to move most units to this level within 2 years. Adjusted EBITDA margin improved to 19%, with further margin expansion of 200 basis poin

Health.GlobalQ3 FY23Healthcare Services

Health.Global Q3 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹694P/E: 215.0Market Cap: ₹10.4K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 2

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Emerging centers are expected to grow faster than mature centers, driven by increased utilization and new patient volumes (Q&A, Page 16).
Continued investment in clinical talent and business promotion will boost future revenues; these investments are temporary and aimed at scalable growth (Page 17).
Focus on increasing volumes first in emerging centers before optimizing mix and ARPOB to improve revenue quality (Page 8).
Growth drivers for FY '24 remain consistent, including improving utilization of emerging hospitals and expansion of clinical services (Page 15-16).
Expansion of capacity with 203 inpatient beds to be operationalized over the next ~18 months, supporting revenue growth (Page 15).
Investments in technology, including robotic surgery and new high-end equipment, to catalyze growth (Page 16).
Emerging centers in bigger cities expected to improve payor mix and ARPOB, enhancing revenue and margins over time (Page 17).
Digital platform modules and increased marketing efforts expected to support volume and revenue growth (Page 5).

Margin guidance

Category 2

The company expects continuation of revenue growth momentum in FY '24 driven by emerging and mature centers.
Emerging centers are investing in clinical talent and sales to drive scale and utilization, leading to future margin improvement.
EBITDA margin currently includes upfront investments but is expected to improve as centers mature, targeting mid-20% unit-level EBITDA margins.
Mature centers typically achieve mid-20% EBITDA margin; the company aims to move most units to this level within 2 years.
Adjusted EBITDA margin improved to 19%, with further margin expansion of 200 basis points seen over 9 months; further 200-300 bps expansion over 2-3 years considered achievable.
Free cash flow expected to improve post current investments, with capex focused on revenue-generating assets without additional borrowing.
Overall, growth drivers include higher patient volumes, better payor mix, increased capacity utilization, and pricing optimizations leading to better profitability and EPS growth.

See what Health.Global management said on margin guidance — free account, 30 seconds.

Fundraise plans

The company plans to fund its growth primarily through internal accruals, avoiding the need for additional borrowing.
Debt-to-EBITDA ratio is currently at a comfortable level (about 2.3%) and is expected to slightly improve in coming quarters.
There will be some capex for maintenance and growth in future years, but this will not require extra borrowing.
No specific mention of new equity fundraising in the provided transcript.
Investments such as new high-end equipment and clinical talent are being funded through existing resources without raising new debt or equity.

Order book

- The expected order book for the Bangalore Center of Excellence (COE) is INR 25 crores with operations expected by Q4 FY '24. - The Karnataka center has invested about INR 18 crores in solar infrastructure, indicating ongoing capital expenditure. - No explicit details on a broader consolidated order book or pending orders were provided in the transcript. - The company is operationalizing installed bed capacity notably in emerging centers like Jaipur (36 additional beds recently operationalized). - Investments are focused on revenue-generating activities such as high-end equipment, robotic surgery, and clinical talent hiring rather than traditional order book execution. - Capital expenditure for new facilities: INR 85 crores expected for a center operational by Q1 FY '25 (location not explicitly mentioned but likely new or specialized centers). Overall, while specific order book values are limited, the company has ongoing capex projects and operational expansions driving future revenues.

See what Health.Global management said on order book — free account, 30 seconds.

Capex plans

Yes

Capex for the 9 months this fiscal was about INR 96 crores, including INR 56 crores invested in various areas.
Investments made in revenue-generating activities such as:
- Solar installation at Karnataka center (~INR 18 crores) reducing electricity cost.
- High-end equipment at the center of excellence.
- Robotic surgery infrastructure including da Vinci robotic units under pay-per-use model.
Future capex includes:
- Capacity additions with expected operationalization of installed beds over the next 18 months.
- Maintenance and growth-oriented capex will continue.
- New centers like the Bangalore COE expected to be operational by Q4 FY '24 and others by Q1 FY '25.
No additional borrowing expected for capex; funded through internal accruals and acceptable debt-to-EBITDA ratios.
Strategic investments focus on clinical talent acquisition, technology adoption (robotics), and marketing to drive growth.

Track Health.Global — get its next earnings analysis in your feed

Margin guidance

Category 2

The company expects continuation of revenue growth momentum in FY '24 driven by emerging and mature centers.
Emerging centers are investing in clinical talent and sales to drive scale and utilization, leading to future margin improvement.
EBITDA margin currently includes upfront investments but is expected to improve as centers mature, targeting mid-20% unit-level EBITDA margins.
Mature centers typically achieve mid-20% EBITDA margin; the company aims to move most units to this level within 2 years.
Adjusted EBITDA margin improved to 19%, with further margin expansion of 200 basis points seen over 9 months; further 200-300 bps expansion over 2-3 years considered achievable.
Free cash flow expected to improve post current investments, with capex focused on revenue-generating assets without additional borrowing.
Overall, growth drivers include higher patient volumes, better payor mix, increased capacity utilization, and pricing optimizations leading to better profitability and EPS growth.

Order book

How does Health.Global rank vs peers in Healthcare Services?

Pro feature

ThisHealth.Global

Rev 2Mar 2

See where Health.Global sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Health.Global rank in Healthcare Services?

Compare Health.Global against every Healthcare Services company (Q3 FY23) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Health.Global's management said in earlier quarters

Others in Healthcare Services this season

Metropolis Healt (Q1 FY27)
East India currently 6%, with limited investment so far; future investments may increase contribution. Key concall takeaways from Metropolis Healthcare Ltd's…
Apollo Hospitals (Q1 FY27)
IP volume growth for established units guided at roughly 7% to 8%. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q1 FY27 earnings call — and how…
Health X Platform (Q1 FY27)
July monthly revenue stood at INR 150+ crores, indicating strong growth momentum. Key concall takeaways from Health X Platform Ltd's Q1 FY27 earnings call…
Shalby (Q1 FY27)
Shalby MedTech showed strong revenue growth: ₹47 crores in Q1 FY27, a 53% YoY increase. Key concall takeaways from Shalby Ltd's Q1 FY27 earnings call — and how…

Compare:vs Apollo Hospitals vs Max Healthcare vs Fortis Health.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Health.Global Q3 FY23 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

Margin guidance

Order book

How does Health.Global rank in Healthcare Services?

Continue your research

What Health.Global's management said in earlier quarters

Others in Healthcare Services this season